CHEK2 and myeloproliferative disorder: Among all diagnosed myeloid malignancies in CHEK2-path patients (N = 35), 34% (12/35) had AML, 26% (9/35) had MDS, 31% (11/35) had MPN, and 9% (3/35) had MDS/MPN (Fig. 2D).